NVAX
Novavax Inc
NASDAQ: NVAX · HEALTHCARE · BIOTECHNOLOGY
$10.32
+2.99% today
Updated 2026-10-28
Market cap
$1.86B
P/E ratio
—
P/S ratio
4.49x
EPS (TTM)
$-1.58
Dividend yield
—
52W range
$6 – $13
Volume
7.2M
Novavax Inc (NVAX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$10.32
12-Month target
$7.47
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.6B | $0.6B | $0.7B | $1.1B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -59.90%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.